Pneumococcal Vaccination Among Medicare Beneficiaries Occurring After the Advisory Committee on Immunization Practices Recommendation for Routine Use Of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults Aged ≥65 Years,"

被引：0
|
作者：
Black, C. L.
Williams, W. W.
Warnock, R.
Pilishvili, T.
Kim, D.
Kelman, J. A.
机构：
来源：
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT | 2017年 / 66卷 / 32期
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：863 / 863
页数：1
相关论文
共 50 条
  • [21] Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults With Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP) (Reprinted from MMWR vol 40, pg 816, 2012)
    Bennett, Nancy M.
    Whitney, Cynthia G.
    Moore, Matt
    Pilishvili, Tamara
    Dooling, Kathleen L.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (04): : 334 - 336
  • [22] Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions
    Cho, Bo-Hyun
    Stoecker, Charles
    Link-Gelles, Ruth
    Moore, Matthew R.
    VACCINE, 2013, 31 (50) : 6011 - 6021
  • [23] Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China
    Mo, Xiuting
    Tobe, Ruoyan Gai
    Liu, Xiaoyan
    Mori, Rintaro
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (11) : E353 - E361
  • [24] Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK
    Jiang, Yiling
    Gauthier, Aline
    Keeping, Sam
    Carroll, Stuart
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (06) : 913 - 927
  • [25] Improved plasmablast response after repeated pneumococcal revaccinations following primary immunization with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia
    Kattstrom, Magdalena
    Uggla, Bertil
    Tina, Elisabet
    Kimby, Eva
    Noren, Torbjorn
    Athlin, Simon
    VACCINE, 2023, 41 (19) : 3128 - 3136
  • [26] Pneumococcal vaccine uptake among Medicare Beneficiaries aged >65 years following the shared clinical decision-making recommendation for 13-valent pneumococcal conjugate vaccine in 2019
    Vietri, Jeffrey
    Sato, Reiko
    Averin, Ahuva
    Weycker, Derek
    Kumar, Mahesh
    Prasad, Sapna
    Chilson, Erica
    VACCINE, 2023, 41 (36) : 5211 - 5215
  • [27] Immunogenicity of the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine in people living with HIV on combination antiretroviral therapy
    Garrido, Hannah M. Garcia
    Schnyder, Jenny L.
    Haydari, Beheshta
    Vollaard, Albert M.
    Tanck, Michael W. T.
    de Bree, Godelieve J.
    Meek, Bob
    Grobusch, Martin P.
    Goorhuis, Abraham
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2022, 60 (02)
  • [28] Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy
    Garcia Garrido, Hannah M.
    Vollaard, Albert
    D'Haens, Geert R.
    Spuls, Phyllis I.
    Bemelman, Frederike J.
    Tanck, Michael W.
    de Bree, Godelieve J.
    Meek, Bob
    Grobusch, Martin P.
    Goorhuis, Abraham
    VACCINES, 2022, 10 (05)
  • [29] Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children
    Sigurdardottir, Sigurveig Th.
    Center, Kimberly J.
    Davidsdottir, Katrin
    Arason, Vilhjalmur A.
    Hjalmarsson, Bjorn
    Elisdottir, Ragnheidur
    Ingolfsdottir, Gunnhildur
    Northington, Robert
    Scott, Daniel A.
    Jonsdottir, Ingileif
    VACCINE, 2014, 32 (03) : 417 - 424
  • [30] A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
    Ngamprasertchai, Thundon
    Kositamongkol, Chayanis
    Lawpoolsri, Saranath
    Rattanaumpawan, Pinyo
    Luvira, Viravarn
    Chongtrakool, Piriyaporn
    Kaewkungwal, Jaranit
    Chokephaibulkit, Kulkanya
    Phisalprapa, Pochamana
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
12345